Cardiology Research and Practice species,” American Journal of Physiology, vol. 275, no. 6, part 1, pp. C1640–C1652, 1998. [66] A. Warnholtz, G. Nickenig, E. Schulz et al., “Increased NADH-oxidase-mediated superoxide production. In the early stages of atherosclerosis evidence for involvement of the renin-angiotensin system,” Circulation, vol. 99, no. 15, pp. 2027–2033, 1999. [67] G. Desideri, M. C. Bravi, M. Tucci et al., “Angiotensin II inhibits endothelial cell motility through an AT-dependent oxidant-sensitive decrement of nitric oxide availability,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 7, pp. 1218–1223, 2003. [68] M. K. Cathcart, “Regulation of superoxide anion production by NADPH oxidase in monocytes/macrophages: contribu- tions to atherosclerosis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 1, pp. 23–28, 2004. [69] K. K. Griendling, C. A. Minieri, J. D. Ollerenshaw, and R. W. Alexander, “Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells,” Circulation Research, vol. 74, no. 6, pp. 1141–1148, 1994. [70] A. W. A. Hahn, “Activation of human peripheral monocytes by angiotensin II,” FEBS Letters, vol. 347, no. 2-3, pp. 178– 180, 1994. [71] A. R. Brasier, M. Jamaluddin, Y. Han, C. Patterson, and M. S. Runge, “Angiotensin II induces gene transcription through cell-type-dependent eﬀects on the nuclear factor-κB (NF-κB) transcription factor,” Molecular and Cellular Biochemistry, vol. 212, no. 1-2, pp. 155–169, 2000. [72] M. Graninger, R. Reiter, C. Drucker, E. Minar, and B. Jilma, “Angiotensin receptor blockade decreases markers of vascular inﬂammation,” Journal of Cardiovascular Pharmacology, vol. 44, no. 3, pp. 335–339, 2004. [73] E. Shagdarsuren, M. Wellner, J. H. Braesen et al., “Comple- ment activation in angiotensin II-induced organ damage,” Circulation Research, vol. 97, no. 7, pp. 716–724, 2005. [74] M. Epstein, “Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift,” Journal of Hypertension, vol. 19, no. 5, pp. 829–842, 2001. [75] T. Hayek, J. Attias, R. Coleman et al., “The angiotensin- converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deﬁcient mice,” Cardiovascular Research, vol. 44, no. 3, pp. 579–587, 1999. [76] S. Keidar, R. Heinrich, M. Kaplan, T. Hayek, and M. Avi- ram, “Angiotensin II administration to atherosclerotic mice increases macrophage uptake of oxidized LDL: a possible role for interleukin-6,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 9, pp. 1464–1469, 2001. [77] O. Soehnlein, S. Eskaﬁ, A. Schmeisser, H. Kloos, W. G. Daniel, and C. D. Garlichs, “Atorvastatin induces tissue transglutaminase in human endothelial cells,” Biochemical and Biophysical Research Communications, vol. 322, no. 1, pp. 105–109, 2004. [78] F. Montecucco, A. Pende, and F. MacH, “The renin- angiotensin system modulates inﬂammatory processes in atherosclerosis: evidence from basic research and clinical studies,” Mediators of Inﬂammation, vol. 2009, Article ID 752406, 2009. [79] U. N. Das, “Is angiotensin-II an endogenous pro- inﬂammatory molecule?” Medical Science Monitor, vol. 11, no. 5, pp. RA155–RA162, 2005. 9 [80] V. Fuster and J. Sanz, “Vascular inﬂammation,” Journal of the American Society of Hypertension, vol. 1, no. 1, pp. 68–81, 2007. [81] A. E. Vendrov, Z. S. Hakim, N. R. Madamanchi, M. Rojas, C. Madamanchi, and M. S. Runge, “Atherosclerosis is attenuated by limiting superoxide generation in both macrophages and vessel wall cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 12, pp. 2714–2721, 2007. [82] P. E. Tummala, XI. L. Chen, C. L. Sundell et al., “Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: a potential link between the renin-angiotensin system and atherosclerosis,” Circulation, vol. 100, no. 11, pp. 1223–1229, 1999. [83] I. C. Haznedaroglu and Y. Beyazit, “Pathobiological aspects of the local bone marrow renin—;angiotensin system: a review,” Journal of the Renin-Angiotensin-Aldosterone System, vol. 11, no. 4, pp. 205–213, 2010. [84] I. C. Haznedaroglu and M. A. O¨ ztu¨rk, “Towards the under- standing of the local hematopoietic bone marrow renin- angiotensin system,” International Journal of Biochemistry and Cell Biology, vol. 35, no. 6, pp. 867–880, 2003. [85] V. J. Jokubaitis, L. Sinka, R. Driessen et al., “Angiotensin- converting enzyme (CD143) marks hematopoietic stem cells in human embryonic, fetal, and adult hematopoietic tissues,” Blood, vol. 111, no. 8, pp. 4055–4063, 2008. [86] E. T. Zambidis, T. S. Park, W. Yu et al., “Expression of angiotensin-converting enzyme (CD143) identiﬁes and regulates primitive hemangioblasts derived from human pluripotent stem cells,” Blood, vol. 112, no. 9, pp. 3601–3614, 2008. [87] H. Goker, I. C. Haznedaroglu, Y. Beyazit et al., “Local umbilical cord blood renin-angiotensin system,” Annals of Hematology, vol. 84, no. 5, pp. 277–281, 2005. [88] K. Acar, Y. Beyazit, A. Sucak et al., “Alterations in the ’local umbilical cord blood renin-angiotensin system’ during pre- eclampsia,” Acta Obstetricia et Gynecologica Scandinavica, vol. 86, no. 10, pp. 1193–1199, 2007. [89] M. A. O¨ ztu¨rk, G. S. Gu¨ven, and I. C. Haznedaroglu, “How hematopoietic stem cells know and act in cardiac microenvironment for stem cell plasticity? Impact of local renin-angiotensin systems,” Medical Hypotheses, vol. 63, no. 5, pp. 866–874, 2004. [90] S. Aksu, Y. Beyazit, I. C. Haznedaroglu et al., “Enhanced expression of the local haematopoietic bone marrow renin- angiotensin system in polycythemia rubra vera,” Journal of International Medical Research, vol. 33, no. 6, pp. 661–667, 2005. [91] S. Aksu, Y. Beyazit, I. C. Haznedaroglu et al., “Over- expression of angiotensin-converting enzyme (CD 143) on leukemic blasts as a clue for the activated local bone marrow RAS in AML,” Leukemia and Lymphoma, vol. 47, no. 5, pp. 891–896, 2006. [92] Y. Beyazit, S. Aksu, I. C. Haznedaroglu et al., “Overexpression of the local bone marrow renin-angiotensin system in acute myeloid leukemia,” Journal of the National Medical Association, vol. 99, no. 1, pp. 57–63, 2007. [93] E. Koca, I. C. Haznedaroglu, K. Acar et al., “Renin- angiotensin system expression in the K562 human ery- throleukaemic cell line,” Journal of the Renin-Angiotensin- Aldosterone System, vol. 8, no. 3, pp. 145–147, 2007. [94] E. Koca, I. C. Haznedaroglu, A. Uner et al., “Angiotensin- converting enzyme expression of the lymphoma-associated macrophages in the lymph nodes of Hodgkin’s disease,”